Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
549
Recruiting, any sponsor type, condition "prostate cancer"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting549
- Completed1,899
549 trials
Showing 1 to 25, recently updated first.
Washington University School of MedicineAcademic, hospital or other
NCT07723651 · 75 participants (planned) · Start Nov 30, 2026 · Primary completion May 31, 2032
Drug: 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one · For: Metastatic Prostate Cancer; Prostate Cancer
Sites: St Louis, Missouri; Philadelphia, Pennsylvania; Houston, Texas
Washington University School of MedicineAcademic, hospital or other
NCT07593079 · 20 participants (planned) · Start Nov 16, 2026 · Primary completion Dec 14, 2027
Drug: Bicalutamide; 18F-rhPSMA-7.3 · For: Prostate Cancer; Recurrent Prostate Cancer; Metastatic Prostate Cancer and 2 more
Sites: St Louis, Missouri
- DESTINY-PANTUMOUR04Recruiting
AstraZenecaAstraZeneca (AZN)
NCT07124000 · 100 participants (planned) · Start Sep 18, 2025 · Primary completion Mar 30, 2028
Drug: Trastuzumab deruxtecan · For: Adenocarcinoma (NOS); Anal Cancer; Bladder Cancer and 24 more
Sites: Birmingham, Alabama; Bullhead City, Arizona; Casa Grande, Arizona · 18 sites in all
National Cancer Institute (NCI)NIH
NCT05616650 · 42 participants (planned) · Start Oct 19, 2023 · Primary completion Dec 1, 2030
Drug: 18F-DCFPyL · For: Prostatic Neoplasms; Prostate Cancer; Prostate Adenocarcinoma
Sites: Bethesda, Maryland
- Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical TherapyRecruiting
University of Wisconsin, MadisonAcademic, hospital or other
NCT07609225 · 15 participants (planned) · Start Oct 16, 2026 · Primary completion Sep 2029
Drug: 3'-Deoxy-3'-[18F]-fluorothymidine · For: Metastatic Castration-resistant Prostate Cancer
Sites: Madison, Wisconsin
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsPivotal-lookingRecruiting
Olema Oncology, Inc.Industry
NCT06784193 · 180 participants (planned) · Start Dec 16, 2024 · Primary completion May 30, 2027
Drug: OP-3136; Fulvestrant and 1 more · For: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC); Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC) and 3 more
Sites: Gilbert, Arizona; Aurora, Colorado; Sarasota, Florida · 25 sites in all
National Cancer Institute (NCI)NIH
NCT07667400 · 120 participants (planned) · Start Nov 25, 2026 · Primary completion Oct 1, 2036
Drug: SX-682; DTX · For: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Paranasal Sinus Neoplasms and 9 more
Sites: Bethesda, Maryland
National Cancer Institute (NCI)NIH
NCT07574541 · 52 participants (planned) · Start Nov 25, 2026 · Primary completion Jun 15, 2028
Drug: TriAdeno vaccine; N-803 · For: Adenocarcinoma; Prostate Cancer; Neoplasms and 3 more
Sites: Bethesda, Maryland
- Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Pivotal-lookingRecruiting
Norroy Bioscience Co., LTDIndustry
NCT07795268 · 600 participants (planned) · Start Nov 13, 2026 · Primary completion Nov 30, 2028
Drug: 177Lu-NYM032 injection · For: Prostate Cancer
Sites: Beijing, China
National Cancer Institute (NCI)NIH
NCT03866382 · 314 participants (planned) · Start May 13, 2019 · Primary completion Feb 28, 2027
Drug: Cabozantinib S-malate; Ipilimumab and 1 more · For: Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Kingman, Arizona · 582 sites in all
National Cancer Institute (NCI)NIH
NCT05691465 · 35 participants (planned) · Start Dec 27, 2023 · Primary completion Jun 1, 2027
Drug: Lutetium Lu 177 Dotatate · For: Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma and 1 more
Sites: Duarte, California; Los Angeles, California; Sacramento, California · 13 sites in all
MultiValent Biotherapies, Inc.Industry
NCT07944508 · 60 participants (planned) · Start Aug 14, 2026 · Primary completion Dec 2027
Drug: MVB-101 · For: Localized Prostate Adenocarcinoma
Sites: Homewood, Alabama; San Antonio, Texas
Yong HeAcademic, hospital or other
NCT07830212 · 50 participants (planned) · Start Oct 10, 2026 · Primary completion Jun 2028
Drug: [68Ga]Ga-OncoACP3 · For: Prostatic Neoplasms; Prostate Cancer
Sites: Wuhan, China
Coherus Oncology, Inc.Industry
NCT07945821 · 12 participants (planned) · Start Nov 2026 · Primary completion Aug 2028
Drug: Tagmokitug; Pasritamig · For: Solid Tumor
Sites: Seattle, Washington
Angela Y. Jia, MD PhDAcademic, hospital or other
NCT06574880 · 45 participants (planned) · Start May 13, 2025 · Primary completion Jan 1, 2027
Drug: Lu-PSMA-617 · For: Malignant Neoplasm of Prostate; Locally Advanced Prostate Cancer
Sites: Cleveland, Ohio
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06172478 · 890 participants (planned) · Start Feb 26, 2024 · Primary completion Nov 19, 2030
Drug: HER3-DXd · For: Advanced Solid Tumor; Melanoma; Head and Neck Cancer and 11 more
Sites: Duarte, California; New Haven, Connecticut; Kissimmee, Florida · 97 sites in all
- Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate CancerRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT05997615 · 347 participants (planned) · Start Aug 10, 2023 · Primary completion Sep 30, 2027
Drug: VIR-5500; Androgen receptor signaling inhibitor (ARSI) and 1 more · For: Hormone-refractory Prostate Cancer
Sites: Duarte, California; Irvine, California; Orange, California · 30 sites in all
- A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate CancerPivotal-lookingRecruiting
BioNTech SEIndustry
NCT07365995 · 736 participants (planned) · Start Apr 22, 2026 · Primary completion Feb 2031
Drug: BNT324; Docetaxel and 1 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Tucson, Arizona; Santa Barbara, California; Aurora, Colorado · 77 sites in all
Hyundai Bioscience Co., Ltd.Industry
NCT07683013 · 18 participants (planned) · Start Aug 3, 2026 · Primary completion Sep 2027
Drug: CP-PCA07; Enzalutamide 40 mg capsule · For: Castration-Resistant Prostate Cancer (CRPC)
Sites: Seoul, South Korea
University of California, San DiegoAcademic, hospital or other
NCT06536374 · 50 participants (planned) · Start Dec 2026 · Primary completion Dec 2027
Drug: Trimethoprim Tablets · For: Prostate Cancer
Sites: La Jolla, California
Jean-Mathieu BeauregardAcademic, hospital or other
NCT07940179 · 5,000 participants (planned) · Start Nov 4, 2021 · Primary completion Dec 31, 2031
Drug: PET PSMA tracer · For: Prostate Cancer; Other Cancers
Sites: Québec, Canada
- A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid TumorsRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07730021 · 392 participants (planned) · Start Sep 2, 2026 · Primary completion Feb 28, 2030
Drug: ASP388B; Pembrolizumab and 3 more · For: Locally Advanced or Metastatic Solid Tumors
Sites: Lake Success, New York; Nashville, Tennessee; Fairfax, Virginia · 5 sites in all
BayerBayer (BAYRY)
NCT07538843 · 800 participants (planned) · Start Jul 31, 2026 · Primary completion Dec 31, 2029
Drug: Darolutamide; ADT · For: Non-metastatic Castration-resistant Prostate Cancer
Sites: Multiple Locations, China
- Carboplatin or Olaparib for BRcA Deficient Prostate CancerPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT04038502 · 100 participants (planned) · Start Oct 1, 2019 · Primary completion Aug 31, 2027
Drug: Carboplatin; Olaparib · For: Metastatic Castrate Resistant Prostate Cancer; BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2; RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Sites: West Los Angeles, California; Aurora, Colorado; Washington D.C., District of Columbia · 18 sites in all
VA Office of Research and DevelopmentFederal agency
NCT05011383 · 51 participants (planned) · Start Aug 31, 2021 · Primary completion Aug 3, 2027
Drug: High dose testosterone · For: Metastatic Prostate Cancer
Sites: Aurora, Colorado; West Haven, Connecticut; Gainesville, Florida · 17 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.